Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab Short Duration Infusion in Advanced Follicular Lymphoma
NCT03817853Phase 4Completed
- Sponsor
- Roche
- Start
- Feb 2019
- Primary completion
- Aug 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 4 trial of obinutuzumab in follicular lymphoma (FL), sponsored by Roche. Started Feb 2019; status: completed.
02
Drugs
obinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03817853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03817853.